WHO Drug Information Vol. 15, No. 2, 2001
(2001; 91 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Ouvrir ce répertoire et afficher son contenuGeneral Information
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentNew Zealand and Australia: joint medicines regulatory body
Afficher le documentBupropion safety information
Afficher le documentBupropion update
Afficher le documentItraconazole and congestive heart failure
Afficher le documentTerbinafine and hepatic failure
Afficher le documentPaediatric amiodarone labelling changes
Afficher le documentCerivastatin: marketing discontinued
Afficher le documentPhenylpropanolamine withdrawn from market
Afficher le documentCounterfeit filgrastim
Afficher le documentOxycodone: strengthened warning
Afficher le documentNesiritide for heart failure
Afficher le documentOprelvekin: paediatric safety information
Afficher le documentPeginterferon alfa-2b combined use: new labelling
Afficher le documentRibavirin for combined use
Afficher le documentSleep attacks with pramipexole and ropinirole
Afficher le documentRosiglitazone-associated hepatic and cardiovascular events
Afficher le documentClarithromycin: labelling change
Afficher le documentHerbal OTC remedy and hepatic dysfunction
Afficher le documentAntipsychotics and high prolactin
Afficher le documentSildenafil: not for use with nitrates
Afficher le documentPropofol, heart failure and high dosages
Afficher le documentBupropion and seizures
Afficher le documentNeurotoxicity with aciclovir and valaciclovir
Afficher le documentRevised labelling for levocarnitine
Afficher le documentAvoid trastuzumab and anthracyclines
Ouvrir ce répertoire et afficher son contenuATC/DDD Classification
Ouvrir ce répertoire et afficher son contenuEssential Drugs
Ouvrir ce répertoire et afficher son contenuRecent Publications and Sources of Information
Afficher le documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
Afficher le documentDénominations communes internationales des Substances pharmaceutiques (DCI)
Afficher le documentDenominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)
Afficher le documentAmendments to previous lists/Modifications apportées aux listes antérieures/Modificaciones a las listas anteriores
Afficher le documentAnnexes
 

Herbal OTC remedy and hepatic dysfunction

Japan - Three cases of hepatic dysfunction have been reported during treatment with the over-the-counter product Seirogan®, which contains glycyrrhizin, creosote, gambir, phellodendron bark and citrus unshiu peel. The product is indicated for the treatment of diarrhoea, vomiting, and food poisoning. The Ministry of Health, Labour and Welfare (MHLW) have responded by calling for hepatic dysfunction to be added to the product label; the paragraph ‘The patient should consult a physician in the following cases’, will describe hepatic dysfunction as a serious adverse event that may rarely occur.

Reference: MHLW Pharmaceuticals and Medical Devices Safety Information. ADR updates from Japan. Media Release, March 2001

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013